TherapeuticsMD (TXMD) Receivables - Net (2010 - 2025)

TherapeuticsMD's Receivables - Net history runs 16 years deep, the most recent figure standing at $17.2 million for Q4 2025.

• Quarterly Receivables - Net fell 11.93% year-over-year to $17.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.2 million (down 11.93% YoY) and the FY2025 annual result came in at $17.2 million, down 11.93% from the prior year.
• Receivables - Net was $17.2 million for Q4 2025 at TherapeuticsMD, down from $19.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $45.8 million in Q2 2022 and bottomed at $17.2 million in Q4 2025.
• A 5-year average of $31.3 million and a median of $33.6 million in 2021 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2021 — Receivables - Net surged 83.05% — and 2022, when it dropped 14.02%.
• TherapeuticsMD's Receivables - Net stood at $36.2 million in 2021, then retreated by 11.11% to $32.2 million in 2022, then slumped by 32.91% to $21.6 million in 2023, then slipped by 9.28% to $19.6 million in 2024, then retreated by 11.93% to $17.2 million in 2025.
• Business Quant data shows TXMD's Receivables - Net at $17.2 million in Q4 2025, $19.6 million in Q4 2024, and $21.6 million in Q4 2023.